Plain-English translation of NCT07025824 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing two different chemotherapy approaches—treosulfan and melphalan—that are given before a stem cell transplant in patients with blood cancers like acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). The study wants to know which chemotherapy option works better and is easier to tolerate, especially for patients who are older or have other health conditions that might make intensive treatment riskier.
Stem cell transplant is a powerful treatment for these blood cancers, but the strong chemotherapy needed beforehand can be very hard on the body, especially for older patients or those with existing health problems. This trial exists to find out which of these two chemotherapy options offers the best balance of effectiveness and safety for these vulnerable patients.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive one of the two chemotherapy regimens in the days leading up to your stem cell transplant. Before the transplant, you'll receive your assigned chemotherapy along with another medication called fludarabine, followed by the stem cell infusion. After transplant, you'll receive a medication called PTCy to help prevent rejection. The study will then monitor you closely for how well the transplant works, how your body handles the treatment, and any side effects, tracking your recovery over time.
AI-generated summary from trial data · Oct 22, 2026 · Not medical advice
Germany